MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03733ntm a2200373 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
vtls000105336 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
KUKTEM |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20251117113407.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180928t20182018my da f a m 001 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
THE0000105(Local) |
| 039 #9 - LEVEL OF BIBLIOGRAPHIC CONTROL AND CODING DETAIL [OBSOLETE] |
|---|
| Level of rules in bibliographic description |
201905311453 |
| Level of effort used to assign nonsubject heading access points |
nazirah |
| -- |
201809281005 |
| -- |
fateeha |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
UMP |
| Language of cataloging |
eng |
| Transcribing agency |
UMP |
| Description conventions |
rda |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
FIST .A33 2018 r Thesis |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Addila Abu Bakar, |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Design, synthesis of flavokawain b derivative and their cytotoxic effects on MCF-7 and MDA-MB-231 cell lines / |
| Statement of responsibility, etc. |
Addila Abu Bakar |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Kuantan, Pahang : |
| Name of producer, publisher, distributor, manufacturer |
UMP, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2018 |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
© 2018 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xxii, 160 pages : |
| Other physical details |
illustrations, charts ; |
| Dimensions |
30 cm. + |
| Accompanying material |
1 CD-ROM |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Source |
rdamedia |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
computer disc |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Faculty of Industrial Sciences and Technology |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Master of Science) -- Universiti Malaysia Pahang – 2018 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Cancer is among the cause of death whereof breast cancer is the second leading cause of cancer death among women worldwide. Cancer treatment with standard anti-cancer drug, chemotherapy and radiation have caused unwanted side effects in the patient. Therefore chalcone with many pharmacological benefits such as anti-cancer, anti-mitotic, etc., has gained attention as a subject of research. Flavokawain B derivative chalcones bearing methoxy, dimethoxy, trimethoxy, bromo, chloro, fluoro, methyl, methylthio, nitro, hydroxyl and dimethylamino groups on benzaldehyde were synthesized via Claisen-Schmidt condensation method using base catalyst; the synthesized compounds were characterized by using UV-Visible, Fourier Transform Infrared spectrophotometry (FTIR), Gas Chromatography-Mass Spectrometry (GC-MS) and Nuclear Magnetic Resonance (NMR) spectrometry and evaluated for their cytotoxicity against breast cancer cell line by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in vitro. Among 22 synthesized compounds, two compounds, 80 and 91 have been discovered as new flavokawain B analogs and some compounds showed good anti-cancer activity following the cut-off point value, IC50 is less than 30 μg/mL. The compounds are chalcone 4 (7.70 ± 0.30 μg/mL), 5 (8.90 ± 0.60 μg/mL), 75 (12.30 ± 1.40 μg/mL), 79 (6.50 ± 0.40 μg/mL), 80 (7.12 ± 0.80 μg/mL), 82 (9.70 ± 0.70 μg/mL), 84 (5.50 ± 0.35 μg/mL), 85 (8.43 ± 0.40 μg/mL), 44 (13.30 ± 3.10 μg/mL) and 91 (6.50 ± 0.35 μg/mL) that exhibited good anti-cancer activity against MCF-7. Chalcone 4 (5.90 ± 0.30 μg/mL), 5 (6.80 ± 0.45 μg/mL), 75 (18.10 ± 1.10 μg/mL), 79 (4.12 ± 0.20 μg/mL), 80 (4.04 ± 0.30 μg/mL), 81 (9.50 ± 0.60 μg/mL), 82 (8.30 ± 0.56 μg/mL), 84 (5.50 ± 0.40 μg/mL), 85 (7.22 ± 0.70 μg/mL) and 44 (17.10 ± 2.15 μg/mL) showed good anti-cancer activity against MDA-MB-231 as well as compound 79 and 80 was discovered to be more active than the reference drug doxorubicin (5.05 ± 0.20 μg/mL). Structure-activity relationship study suggested that significantly improved cytotoxicity was shown by halogenated flavokawain B, followed by methoxylated flavokawain B, particularly when substitution occurred at position 2 and 3 in ring B. |
| 610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Faculty of Industrial Sciences and Technology |
| General subdivision |
Dissertations |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Universities and colleges |
| General subdivision |
Disertations |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Theses |